Noile-Immune Biotech (TSE:4893) Other Financing: 円0.00 Mil (TTM As of Dec. 2025)


TSE:4893 Noile-Immune Biotech Inc TSE:4893
49 GF Score
Price 円136.00
GF Value 円4.34
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Noile-Immune Biotech Other Financing?

Noile-Immune Biotech TSE:4893 +5.43% 49 Other Financing is 円0.00 Mil as of Dec. 2025. GuruFocus rates TSE:4893 with a GF Score™ of 49/100 and a GF Value™ of 円4.34 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Noile-Immune Biotech's Other Financing for the three months ended in Dec. 2025 was 円0.00 Mil.

Noile-Immune Biotech's Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 was 円0.00 Mil.

Noile-Immune Biotech Other Financing Historical Data

* Premium members only.

The historical data trend for Noile-Immune Biotech's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Noile-Immune Biotech Other Financing Chart

Noile-Immune Biotech Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial 0.00 -10.70 -594.95 0.00 0.00

Noile-Immune Biotech Quarterly Data
Dec20 Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TSE:4893
49GF Score
Noile-Immune Biotech Inc TSE:4893
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Noile-Immune Biotech Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of 円0.00 Mil mean?
Noile-Immune Biotech (TSE:4893) has a Other Financing of 円0.00 Mil as of Dec. 2025. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Noile-Immune Biotech and its competitors.
Is Noile-Immune Biotech's Other Financing too high?
Noile-Immune Biotech's current Other Financing is 円0.00 Mil. Overall, Noile-Immune Biotech has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Noile-Immune Biotech's Other Financing compare to VRTX and REGN?
Noile-Immune Biotech's Other Financing of 円0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Noile-Immune Biotech and its competitors. Noile-Immune Biotech's current Other Financing is 円0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Noile-Immune Biotech stock overvalued right now?
Based on GuruFocus' analysis, Noile-Immune Biotech (TSE:4893) is currently considered Significantly Overvalued. The stock's GF Value™ is 円4.34, compared to a current price of 円136.00 — trading 3033.6% above its estimated fair value. The current Other Financing is 円0.00 Mil. Noile-Immune Biotech's overall GF Score™ is 49/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Noile-Immune Biotech (TSE:4893), the current Other Financing is 円0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Noile-Immune Biotech (TSE:4893) Overvalued in 2026?

Based on GuruFocus' analysis, Noile-Immune Biotech stock appears to be overvalued. The current stock price of 円136.00 is trading 3033.6% above its estimated GF Value™ of 円4.34. GuruFocus considers Noile-Immune Biotech to be Significantly Overvalued.

Key valuation signals for TSE:4893:

  • Other Financing: 円0.00 Mil
  • GF Value™: 円4.34 vs. price of 円136.00 (3033.6% above fair value)
  • GF Score™: 49/100 with 2 warning signs

No single metric tells the full story. See the TSE:4893 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Noile-Immune Biotech Business Description

Address 2-12-10 Shiba-Daimon, 5th Floor, T&G Hamamatsucho Building, Minato-ku, Yamaguchi, Tokyo, JPN, 105-0012
Noile-Immune Biotech Inc is engaged in the development of CAR-T cell therapy for solid cancers using its proprietary technology. The company's development pipeline and collaborative projects with other companies include different product candidates such as NIB102, NIB103, NIB104, ADAP01, AUTL01, etc. It operates in a single segment, the cancer immunotherapy drug discovery business.
49GF Score

Get the complete analysis for TSE:4893

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円136.00
Price
円4.34
GF Value